CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia

Article Hematology

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Allison Barz Leahy et al.

Summary: Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed/refractory B-acute lymphoblastic leukemia (ALL), regardless of different cytogenetic characteristics. High-risk patients, including those with KMT2A-rearranged infant ALL, showed high probabilities of relapse-free survival and overall survival at 2 years.

BLOOD (2022)

Add to Collection

Review Oncology

Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens A Review

Elias Jabbour et al.

Summary: The integration of TKIs into chemotherapy regimens has greatly improved the outcomes of patients with Ph-positive ALL, with higher remission rates and longer survival. Early achievement of CMR has become an important predictor of long-term survival and may eliminate the need for allogeneic SCT. Second-generation TKIs combined with chemotherapy have shown superior results compared to imatinib-based regimens. The addition of third-generation TKI ponatinib to chemotherapy further enhances the outcomes. In recent chemotherapy-free regimens, blinatumomab plus TKIs have shown promising results, questioning the necessity of allogeneic SCT in first remission.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia

Tongyan Meng et al.

Summary: This retrospective analysis of 30 AYA patients with ETP-ALL who underwent allo-HSCT showed that disease status prior to transplant significantly impacted overall survival rates. Patients transplanted in CR1/2 had better outcomes compared to those with active disease, highlighting the importance of disease status in predicting survival outcomes.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial

Franco Locatelli et al.

Summary: This study compared the effects of blinatumomab with consolidation chemotherapy as a third consolidation block before allogeneic hematopoietic stem cell transplant in children with high-risk first-relapse B-ALL. The results showed that, compared to chemotherapy, treatment with blinatumomab significantly improved event-free survival in children with high-risk first-relapse B-ALL.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Review Hematology